文献速递胸部肿瘤泌尿男性生殖肿瘤妇科肿瘤

端粒长度与癌症及非肿瘤性疾病风险的关联:一项孟德尔随机化研究

Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study.
PubMed 文献 · JAMA Oncol · 2017-01-01

该孟德尔随机化研究利用生殖系遗传变异作为工具变量,评估端粒长度与癌症及非肿瘤性疾病风险的因果关联。结果显示,遗传决定的端粒长度增加与多种部位特异性癌症风险升高相关,而与冠心病、腹主动脉瘤、乳糜泻和间质性肺病风险降低相关。

要点

  • 遗传决定的端粒长度每增加1个标准差,胶质瘤风险OR为5.27(95%CI 3.15-8.81)。
  • 端粒长度增加与肺癌腺癌、膀胱癌、黑色素瘤等多种癌症风险升高相关。
  • 端粒长度增加与冠心病风险降低相关,OR为0.78(95%CI 0.67-0.90)。

核心结论

  • 遗传决定的端粒长度增加可能提高多种癌症风险,但降低包括心血管疾病在内的部分非肿瘤性疾病风险。

研究设计与样本

  • 孟德尔随机化研究,使用生殖系遗传变异作为工具变量。
  • 数据来源为截至2015年1月15日发表的GWAS,最终纳入103项GWAS的汇总数据。
  • 汇总数据涵盖35种癌症和48种非肿瘤性疾病,对应420081例病例和1093105例对照。

主要发现

  • 遗传决定的端粒长度每增加1个标准差,胶质瘤风险OR为5.27(95%CI 3.15-8.81)。
  • 遗传决定的端粒长度每增加1个标准差,浆液性低度恶性潜能卵巢癌风险OR为4.35(95%CI 2.39-7.94),肺腺癌OR为3.19(95%CI 2.40-4.22),神经母细胞瘤OR为2.98(95%CI 1.92-4.62)。
  • 遗传决定的端粒长度每增加1个标准差,膀胱癌风险OR为2.19(95%CI 1.32-3.66),黑色素瘤OR为1.87(95%CI 1.55-2.26),睾丸癌OR为1.76(95%CI 1.02-3.04)。
  • 遗传决定的端粒长度每增加1个标准差,肾癌风险OR为1.55(95%CI 1.08-2.23),子宫内膜癌OR为1.31(95%CI 1.07-1.61)。
  • 遗传决定的端粒长度增加与冠心病风险降低相关,OR为0.78(95%CI 0.67-0.90);与腹主动脉瘤风险降低相关,OR为0.63(95%CI 0.49-0.81);与乳糜泻风险降低相关,OR为0.42(95%CI 0.28-0.61);与间质性肺病风险降低相关,OR为0.09(95%CI 0.05-0.15)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The causal direction and magnitude of the association between telomere length and incidence of cancer and non-neoplastic diseases is uncertain owing to the susceptibility of observational studies to confounding and reverse causation. OBJECTIVE: To conduct a Mendelian randomization study, using germline genetic variants as instrumental variables, to appraise the causal relevance of telomere length for risk of cancer and non-neoplastic diseases. DATA SOURCES: Genomewide association studies (GWAS) published up to January 15, 2015. STUDY SELECTION: GWAS of noncommunicable diseases that assayed germline genetic variation and did not select cohort or control participants on the basis of preexisting diseases. Of 163 GWAS of noncommunicable diseases identified, summary data from 103 were available. DATA EXTRACTION AND SYNTHESIS: Summary association statistics for single nucleotide polymorphisms (SNPs) that are strongly associated with telomere length in the general population. MAIN OUTCOMES AND MEASURES: Odds ratios (ORs) and 95% confidence intervals (CIs) for disease per standard deviation (SD) higher telomere length due to germline genetic variation. RESULTS: Summary data were available for 35 cancers and 48 non-neoplastic diseases, corresponding to 420 081 cases (median cases, 2526 per disease) and 1 093 105 controls (median, 6789 per disease). Increased telomere length due to germline genetic variation was generally associated with increased risk for site-specific cancers. The strongest associations (ORs [95% CIs] per 1-SD change in genetically increased telomere length) were observed for glioma, 5.27 (3.15-8.81); serous low-malignant-potential ovarian cancer, 4.35 (2.39-7.94); lung adenocarcinoma, 3.19 (2.40-4.22); neuroblastoma, 2.98 (1.92-4.62); bladder cancer, 2.19 (1.32-3.66); melanoma, 1.87 (1.55-2.26); testicular cancer, 1.76 (1.02-3.04); kidney cancer, 1.55 (1.08-2.23); and endometrial cancer, 1.31 (1.07-1.61). Associations were stronger for rarer cancers and at tissue sites with lower rates of stem cell division. There was generally little evidence of association between genetically increased telomere length and risk of psychiatric, autoimmune, inflammatory, diabetic, and other non-neoplastic diseases, except for coronary heart disease (OR, 0.78 [95% CI, 0.67-0.90]), abdominal aortic aneurysm (OR, 0.63 [95% CI, 0.49-0.81]), celiac disease (OR, 0.42 [95% CI, 0.28-0.61]) and interstitial lung disease (OR, 0.09 [95% CI, 0.05-0.15]). CONCLUSIONS AND RELEVANCE: It is likely that longer telomeres increase risk for several cancers but reduce risk for some non-neoplastic diseases, including cardiovascular diseases.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Haycock PC, Burgess S, Nounu A, et al. Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. JAMA Oncol. 2017. PMID: 28241208. doi:10.1001/jamaoncol.2016.5945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。